Buscar
Congreso SOLACI

Artículos del autor

Dr. Andrés Rodríguez

Member of the Editorial Board of solaci.org
Chronic Coronary Syndromes

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization....
Dr. Andrés Rodríguez -
Coronary disease

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD)....
Dr. Andrés Rodríguez -
Coronary disease

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well...
Dr. Andrés Rodríguez -
Chronic Ischemic cardiopathy

Early and Late Outcomes with the ABSORB Bioresorbable Scaffold

Coronary angioplasty with drug-eluting stents (DES) is associated with a 2-3% annual incidence of stent-related events, a...
Dr. Andrés Rodríguez -
Carotid

PERFORMANCE II Trial: Safety and Efficacy of the New NeuroGuard Carotid Stent System

The percutaneous treatment of carotid artery disease through stenting (CAS) for the prevention of cerebrovascular disease has...
Dr. Andrés Rodríguez -
Chronic Coronary Syndromes

Discordance between Physiology and Imaging Guided PCI in Intermediate Coronary Lesions: Who to trust?

As regards intermediate coronary lesion intervention, physiological assessment is essential for culprit lesion identification and clinical decision...
Dr. Andrés Rodríguez -
Chronic Coronary Syndromes

FAVOR III Europa Sub-Analysis: Coronary Revascularization Deferral Based On QFR vs FFR

When it comes to intermediate coronary lesion revascularization decision making, functional assessment is the recommended. At present,...
Dr. Andrés Rodríguez -
Structural heart disease

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe...
Dr. Andrés Rodríguez -

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad